TGFB1 and neoplasm: Pharmacological inhibition of NOX4 using GKT137831, an oral drug developed as an anti-fibrotic agent, abrogated TGFβ-dependent ROS production, myofibroblast transdifferentiation, and slow tumor growth (70).